Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05231 (
interleukin-6
)
23,907
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Circulating
interleukin-6
(
IL-6
), insulin, and free fatty acid (FFA) concentrations are associated with impaired insulin action in obese and type 2 diabetic individuals. However, a causal relationship between elevated plasma FFAs and
IL-6
has not been shown. Because skeletal muscle represents a major target of impaired insulin action, we studied whether FFAs may affect
IL-6
expression in human myotubes. We demonstrate that specifically saturated FFAs, e.g. palmitate (0.25 mm), induce
IL-6
mRNA expression and protein secretion by a proteasome-dependent mechanism that leads to a rapid and chronic activation of nuclear factor-kappaB. Insulin, high glucose concentrations, or unsaturated FFAs did not activate
IL-6
expression. In fact, the unsaturated FFA linoleate inhibited palmitate-induced
IL-6
production. Because inhibition of palmitate metabolism by the
acyl-CoA synthetase
inhibitor triacsin C did not abolish
IL-6
expression, it appears that the palmitate molecule per se exerts the observed effects. Furthermore, we show that in human myotubes,
IL-6
activates the phosphorylation of signal transducer and activator of transcription 3 in concentrations similar to hepatocytes. However, no inhibitory effect of
IL-6
on insulin action, determined as phosphatidylinositol 3-kinase association with insulin receptor substrate-1, Akt phosphorylation, and glycogen synthesis, was detected. We conclude that
IL-6
expression may be modulated by the composition of circulating FFA, e.g. by diet, and that skeletal muscle cells could be target cells for
IL-6
.
...
PMID:Palmitate, but not unsaturated fatty acids, induces the expression of interleukin-6 in human myotubes through proteasome-dependent activation of nuclear factor-kappaB. 1502 33